Based on this literature, different molecules that directly or indirectly activate AMPK, such as metformin (already widely used to treat type 2 diabetes mellitus), have been identified as efficient inhibitors of the progression of renal diseases, including polycystic kidney disease, renal cancer or acute kidney injury69,72,73. Here, PRKAA1 is linked to renal carcinoma.